About Liraglutide (Victoza)
Victoza contains Liraglutide, a GLP-1 receptor agonist injectable prescribed for type 2 diabetes management and cardiovascular risk reduction. It reduces blood glucose, promotes weight loss, and has proven cardiovascular benefits in at-risk patients.
Benefits of Liraglutide (Victoza)
- Glycaemic Control: Significantly reduces HbA1c and fasting blood glucose.
- Weight Loss: Promotes meaningful body weight reduction.
- Cardiovascular Protection: Reduces major adverse cardiovascular events in high-risk patients.
How Liraglutide Works
Liraglutide is a long-acting GLP-1 analogue that activates GLP-1 receptors in pancreatic beta cells to stimulate glucose-dependent insulin secretion and suppress glucagon. It slows gastric emptying and activates central appetite centres, contributing to weight loss.
Dosage & Usage
- Dosage: Subcutaneous injection once daily as prescribed; dose titration required.
- Precautions: Not for type 1 diabetes; monitor for pancreatitis and thyroid C-cell changes.
Side Effects
- Nausea or vomiting
- Diarrhoea or constipation
- Injection site reactions
Consult your doctor before use.





Write a review